{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:41:28Z","timestamp":1793328088724,"version":"4.5.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Venous thromboembolism (VTE) is a life-threating condition that is common in patients with adult-type diffuse gliomas, yet thromboprophylaxis is controversial because of possible intracerebral hemorrhage. Effective VTE prediction models exist for other cancers, but not glioma. Our objective was to develop a VTE prediction tool to improve glioma patient care, incorporating clinical, blood-based, histologic, and molecular markers. We analyzed preoperative arterial blood, tumor tissue, and clinical-pathologic data (including next-generation sequencing data) from 258 patients with newly diagnosed World Health Organization (WHO) grade 2 to 4 adult-type diffuse gliomas. Forty-six (17.8%) experienced VTE. Tumor expression of tissue factor (TF) and podoplanin (PDPN) each positively correlated with VTE, although only circulating TF and D-dimers, not circulating PDPN, correlated with VTE risk. Gliomas with mutations in isocitrate dehydrogenase 1 (IDH1) or IDH2 (IDHmut) caused fewer VTEs; multivariable analysis suggested that this is due to IDHmut suppression of TF, not PDPN. In a predictive time-to-event model, the following predicted increased VTE risk in newly diagnosed patients with glioma: (1) history of VTE; (2) hypertension; (3) asthma; (4) white blood cell count; (5) WHO tumor grade; (6) patient age; and (7) body mass index. Conversely, IDHmut, hypothyroidism, and MGMT promoter methylation predicted reduced VTE risk. These 10 variables were used to create a web-based VTE prediction tool that was validated in 2 separate cohorts of patients with adult-type diffuse glioma from other institutions. This study extends our understanding of the VTE landscape in these tumors and provides evidence-based guidance for clinicians to mitigate VTE risk in patients with glioma.<\/jats:p>","DOI":"10.1182\/blood.2022017858","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T21:16:22Z","timestamp":1668806182000},"page":"1322-1336","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["Determining venous thromboembolism risk in patients with adult-type diffuse glioma"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3720-2795","authenticated-orcid":false,"given":"Kirsten Bell","family":"Burdett","sequence":"first","affiliation":[{"name":"1Department of Preventive Medicine, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusten","family":"Unruh","sequence":"additional","affiliation":[{"name":"2Bio-Techne, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Drumm","sequence":"additional","affiliation":[{"name":"3Department of Neurological Surgery, Northwestern University, Chicago, IL"},{"name":"4Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Steffens","sequence":"additional","affiliation":[{"name":"3Department of Neurological Surgery, Northwestern University, Chicago, IL"},{"name":"4Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lamano","sequence":"additional","affiliation":[{"name":"5Department of Neurosurgery, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Judkins","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Oregon Health and Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Schwartz","sequence":"additional","affiliation":[{"name":"3Department of Neurological Surgery, Northwestern University, Chicago, IL"},{"name":"4Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Javier","sequence":"additional","affiliation":[{"name":"7University of Chicago Pritzker School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4558-8664","authenticated-orcid":false,"given":"Christina","family":"Amidei","sequence":"additional","affiliation":[{"name":"3Department of Neurological Surgery, Northwestern University, Chicago, IL"},{"name":"4Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4372-5533","authenticated-orcid":false,"given":"Eric S.","family":"Lipp","sequence":"additional","affiliation":[{"name":"8The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Peters","sequence":"additional","affiliation":[{"name":"8The Preston Robert Tisch Brain Tumor Center, Department of Neurosurgery, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Lai","sequence":"additional","affiliation":[{"name":"9Department of Neurology, University of California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3351-3895","authenticated-orcid":false,"given":"Blaine S. C.","family":"Eldred","sequence":"additional","affiliation":[{"name":"9Department of Neurology, University of California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-8695","authenticated-orcid":false,"given":"Amy B.","family":"Heimberger","sequence":"additional","affiliation":[{"name":"3Department of Neurological Surgery, Northwestern University, Chicago, IL"},{"name":"4Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7085-830X","authenticated-orcid":false,"given":"Kathleen","family":"McCortney","sequence":"additional","affiliation":[{"name":"3Department of Neurological Surgery, Northwestern University, Chicago, IL"},{"name":"4Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise M.","family":"Scholtens","sequence":"additional","affiliation":[{"name":"1Department of Preventive Medicine, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-9992","authenticated-orcid":false,"given":"Craig","family":"Horbinski","sequence":"additional","affiliation":[{"name":"3Department of Neurological Surgery, Northwestern University, Chicago, IL"},{"name":"4Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"},{"name":"10Department of Pathology, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2023103115012852800_bib1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023103115012852800_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E","article-title":"The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review","volume":"89","author":"Marras","year":"2000","journal-title":"Cancer"},{"issue":"suppl 4","key":"2023103115012852800_bib3","doi-asserted-by":"crossref","first-page":"iv73","DOI":"10.1093\/neuonc\/nos197","article-title":"Thromboembolic disease in patients with high-grade glioma","volume":"14","author":"Perry","year":"2012","journal-title":"Neuro Oncol"},{"issue":"2","key":"2023103115012852800_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1538-7836.2009.03690.x","article-title":"Venous thromboembolism in malignant gliomas","volume":"8","author":"Jenkins","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"23 suppl 1","key":"2023103115012852800_bib5","first-page":"I17","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"2023103115012852800_bib6","first-page":"601","article-title":"Epidemiology of venous thromboembolism in 9489 patients with malignant glioma","volume":"106","author":"Semrad","year":"2007","journal-title":"J\u00a0Neurosurg"},{"issue":"10","key":"2023103115012852800_bib7","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2023103115012852800_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11060-014-1557-4","article-title":"Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period","volume":"120","author":"Smith","year":"2014","journal-title":"J\u00a0Neurooncol"},{"key":"2023103115012852800_bib9","doi-asserted-by":"crossref","first-page":"106792","DOI":"10.1016\/j.clineuro.2021.106792","article-title":"Optimal timing of post-operative enoxaparin after neurosurgery: a single institution experience","volume":"207","author":"Briggs","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"2023103115012852800_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0034-1370791","article-title":"Thrombosis in brain tumors","volume":"40","author":"Jo","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"9","key":"2023103115012852800_bib11","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A\u00a0meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2023103115012852800_bib12","first-page":"87","article-title":"Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism","volume":"3","author":"Khoury","year":"2016","journal-title":"Neurooncol Pract"},{"key":"2023103115012852800_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.thromres.2017.06.010","article-title":"Management of venous thromboembolism in patients with glioma","volume":"156","author":"Al Megren","year":"2017","journal-title":"Thromb Res"},{"issue":"25","key":"2023103115012852800_bib14","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood-2017-02-767285","article-title":"Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin","volume":"129","author":"Mantia","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2023103115012852800_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/neuonc\/noab198","article-title":"Management of venous thromboembolism in high-grade glioma: does low molecular weight heparin increase intracranial bleeding risk?","volume":"24","author":"Jo","year":"2022","journal-title":"Neuro Oncol"},{"issue":"5","key":"2023103115012852800_bib16","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.3171\/2012.7.FOCUS12183","article-title":"Patterns in neurosurgical adverse events: intracranial neoplasm surgery","volume":"33","author":"Wong","year":"2012","journal-title":"Neurosurg Focus"},{"issue":"1","key":"2023103115012852800_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11060-015-1805-2","article-title":"Venous thromboembolism (VTE) and glioblastoma","volume":"124","author":"Yust-Katz","year":"2015","journal-title":"J\u00a0Neurooncol"},{"issue":"1","key":"2023103115012852800_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.thromres.2013.09.011","article-title":"Risk factors for inpatient venous thromboembolism despite thromboprophylaxis","volume":"133","author":"Wang","year":"2014","journal-title":"Thromb Res"},{"issue":"10","key":"2023103115012852800_bib19","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0959-8049(97)00167-6","article-title":"Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study","volume":"33","author":"Brandes","year":"1997","journal-title":"Eur J Cancer"},{"issue":"12","key":"2023103115012852800_bib20","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/neuonc\/nou106","article-title":"Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas","volume":"16","author":"Thaler","year":"2014","journal-title":"Neuro Oncol"},{"issue":"10","key":"2023103115012852800_bib21","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2023103115012852800_bib22","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"2023103115012852800_bib23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00401-013-1106-9","article-title":"What do we know about IDH1\/2 mutations so far, and how do we use it?","volume":"125","author":"Horbinski","year":"2013","journal-title":"Acta Neuropathol"},{"issue":"6","key":"2023103115012852800_bib24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00401-016-1620-7","article-title":"Mutant IDH1 and thrombosis in gliomas","volume":"132","author":"Unruh","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2023103115012852800_bib25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/1078-0432.CCR-18-1222","article-title":"Methylation-dependent tissue factor suppression contributes to the reduced malignancy of IDH1 mutant gliomas","volume":"25","author":"Unruh","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2023103115012852800_bib26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00401-016-1620-7","article-title":"Mutant IDH1 and thrombosis in gliomas","volume":"132","author":"Unruh","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"1","key":"2023103115012852800_bib27","doi-asserted-by":"crossref","first-page":"8946","DOI":"10.1038\/s41598-019-45346-1","article-title":"Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers","volume":"9","author":"Unruh","year":"2019","journal-title":"Sci Rep"},{"issue":"13","key":"2023103115012852800_bib28","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2016-06-720714","article-title":"Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism","volume":"129","author":"Riedl","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2023103115012852800_bib29","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jth.14129","article-title":"Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism","volume":"16","author":"Mir Seyed Nazari","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"22","key":"2023103115012852800_bib30","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.2019001388","article-title":"Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin","volume":"134","author":"Suzuki-Inoue","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2023103115012852800_bib31","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1182\/bloodadvances.2020002998","article-title":"Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles","volume":"5","author":"Tawil","year":"2021","journal-title":"Blood Adv"},{"key":"2023103115012852800_bib32","doi-asserted-by":"crossref","first-page":"e982","DOI":"10.1016\/j.wneu.2019.05.049","article-title":"Podoplanin expression and IDH-wildtype status predict venous thromboembolism in patients with high-grade gliomas in the early postoperative period","volume":"128","author":"Watanabe","year":"2019","journal-title":"World Neurosurg"},{"issue":"suppl 1","key":"2023103115012852800_bib33","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0049-3848(12)70015-4","article-title":"Oncogenic regulation of tissue factor and thrombosis in cancer","volume":"129","author":"Anand","year":"2012","journal-title":"Thromb Res"},{"issue":"1","key":"2023103115012852800_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.V64.1.177.177","article-title":"Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis","volume":"64","author":"Bastida","year":"1984","journal-title":"Blood"},{"issue":"10","key":"2023103115012852800_bib35","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1158\/1078-0432.CCR-06-2351","article-title":"Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer","volume":"13","author":"Khorana","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2023103115012852800_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.thromres.2009.09.019","article-title":"Increased microparticle tissue factor activity in cancer patients with venous thromboembolism","volume":"125","author":"Manly","year":"2010","journal-title":"Thromb Res"},{"issue":"4","key":"2023103115012852800_bib37","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0039-1687895","article-title":"Role of tissue factor in tumor progression and cancer-associated thrombosis","volume":"45","author":"Rondon","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"7","key":"2023103115012852800_bib38","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1538-7836.2012.04754.x","article-title":"Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients","volume":"10","author":"Thaler","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"22","key":"2023103115012852800_bib39","doi-asserted-by":"crossref","first-page":"6830","DOI":"10.1158\/1078-0432.CCR-09-0371","article-title":"Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy","volume":"15","author":"Zwicker","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023103115012852800_bib40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/neuonc\/nov289","article-title":"Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors","volume":"18","author":"Nikiforova","year":"2016","journal-title":"Neuro Oncol"},{"issue":"15","key":"2023103115012852800_bib41","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.2018.14346","article-title":"Venous thromboembolism: advances in diagnosis and treatment","volume":"320","author":"Tritschler","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"2023103115012852800_bib42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.0006-341X.2005.030814.x","article-title":"Survival model predictive accuracy and ROC curves","volume":"61","author":"Heagerty","year":"2005","journal-title":"Biometrics"},{"key":"2023103115012852800_bib43","author":"R Development Core Team","year":"2018"},{"issue":"4","key":"2023103115012852800_bib44","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jth.12510","article-title":"Strengths and weaknesses of a new mouse model of thrombosis induced by inferior vena cava stenosis: communication from the SSC of the ISTH","volume":"12","author":"Geddings","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"29","key":"2023103115012852800_bib45","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"2023103115012852800_bib46","doi-asserted-by":"crossref","first-page":"117538","DOI":"10.1016\/j.jns.2021.117538","article-title":"IDH mutation status and the development of venous thromboembolism in astrocytoma patients","volume":"427","author":"Mandel","year":"2021","journal-title":"J\u00a0Neurol Sci"},{"issue":"3","key":"2023103115012852800_bib47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s10014-021-00406-1","article-title":"Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma","volume":"38","author":"Osada","year":"2021","journal-title":"Brain Tumor Pathol"},{"issue":"15","key":"2023103115012852800_bib48","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020007488","article-title":"Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors","volume":"137","author":"Dunbar","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2023103115012852800_bib49","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/jth.15739","article-title":"Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma","volume":"20","author":"Kaptein","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"2023103115012852800_bib50","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1212\/WNL.0000000000011414","article-title":"Risk of venous thromboembolism in grade II-IV gliomas as a function of molecular subtype","volume":"96","author":"Diaz","year":"2021","journal-title":"Neurology"},{"key":"2023103115012852800_bib51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2022.08.029","article-title":"Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: a systematic review and meta-analysis","volume":"219","author":"Low","year":"2022","journal-title":"Thromb Res"},{"issue":"11","key":"2023103115012852800_bib52","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2013-04-460139","article-title":"Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients","volume":"122","author":"Geddings","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2023103115012852800_bib53","first-page":"378","article-title":"Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role","volume":"110","author":"Sartori","year":"2013","journal-title":"Thromb Haemost"},{"issue":"1","key":"2023103115012852800_bib54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11060-010-0462-8","article-title":"Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles","volume":"104","author":"Sartori","year":"2011","journal-title":"J\u00a0Neurooncol"},{"key":"2023103115012852800_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2016.01.011","article-title":"Measurement of microparticle tissue factor activity in clinical samples: a summary of two tissue factor-dependent FXa generation assays","volume":"139","author":"Hisada","year":"2016","journal-title":"Thromb Res"},{"issue":"6","key":"2023103115012852800_bib56","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/CCO.0000000000000226","article-title":"Venous thrombosis in patients with high-grade glioma","volume":"27","author":"Taillibert","year":"2015","journal-title":"Curr Opin Oncol"},{"issue":"18","key":"2023103115012852800_bib57","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1101\/gad.198200.112","article-title":"D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function","volume":"26","author":"Sasaki","year":"2012","journal-title":"Genes Dev"},{"issue":"7","key":"2023103115012852800_bib58","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1007\/s00520-022-07050-1","article-title":"Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma","volume":"30","author":"Huang","year":"2022","journal-title":"Support Care Cancer"},{"issue":"10","key":"2023103115012852800_bib59","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/11\/1322\/2086577\/blood_bld-2022-017858-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/11\/1322\/2086577\/blood_bld-2022-017858-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T15:02:49Z","timestamp":1698764569000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/11\/1322\/493282\/Determining-venous-thromboembolism-risk-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,3,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017858","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}